Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Panobinostat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Combo of Panobinostat and Carfilzomib | EXPERIMENTAL | A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week. |
| Name | Type | Description |
|---|---|---|
| Panobinostat | DRUG | Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week. * Standard 3+3 design * 3 out of 4 weeks |
| Carfilzomib | DRUG | Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment. * Standard 3+3 design * Days 1/2, 8/9 and 15/16 every 4 weeks |
| Dexamethasone | DRUG | Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib. |
Inclusion Criteria: 1. Male or female patients aged ≥ 18 years old 2. Diagnosis of multiple myeloma (MM) following at least one prior therapy; there is no maximum number or prior therapies 3. Patients must have relapsed/ refractory disease and be in need of therapy with evidence of measurable disea...
Top 20 of 25 competitors
Panobinostat is an investigational small molecule being studied for the treatment of Multiple Myeloma. It is a histone deacetylase inhibitor that is being evaluated in combination with carfilzomib for patients with relapsed and/or refractory Multiple Myeloma. The drug is currently in Phase 1 clinical development.
Panobinostat is a histone deacetylase inhibitor. It works by inhibiting histone deacetylase enzymes, which play a role in gene expression and protein activity. This mechanism is being studied for its potential anti-cancer effects in Multiple Myeloma.
Panobinostat is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Multiple Myeloma.
Panobinostat is currently in Phase 1 clinical development for Multiple Myeloma. It is an investigational drug and has not been approved by the FDA. The ongoing clinical program is evaluating the drug in combination with carfilzomib for patients with relapsed and/or refractory disease.
Panobinostat is being studied in a Phase 1 clinical trial with the identifier NCT01549431. This completed trial, titled 'Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma,' enrolled 32 participants in the United States. The study was uncontrolled and not randomized or double-blinded.
Panobinostat is also known as LBH589. This alternative name is used in some clinical and scientific contexts to refer to the same drug. Both names refer to the histone deacetylase inhibitor being developed by Amgen Inc. for the treatment of Multiple Myeloma.